Lupin divests Kyowa Criticare to Neopharma group
22nd Aug 2019

Lupin has entered into a definitive agreement through its Japanese subsidiary Kyowa (Kyowa Pharmaceutical Industry) for the sale of its Japanese Injectables business and related assets in Japan to neo ALA a wholly owned subsidiary of Neopharma group, the UAE's largest pharmaceutical manufacturer headquartered in Abu Dhabi. The plant and associated facilities are based out of Atsugi, Japan and has been engaged in sales and contract manufacturing of injectable products to meet various medical needs.

Under the terms of the agreement, the company has agreed to sell all the issued and outstanding share capital in Kyowa Criticare to neo ALA. The transaction is subject to customary closing conditions and has been approved by the Board of Directors of the company. This transaction does not involve or affect the other operations of Kyowa, namely research, manufacturing, marketing and distribution of oral solids and other dosage forms in Japan.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.